Longeveron Inc.

Greetings and welcome to the Longevron second quarter 2023 earnings call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce host Mike Moyer, investor relations. Thank you, sir. You may begin.

Thank you, operator.

Good morning, everyone, and welcome to Longevaron's second quarter 2023 results conference call. Today, we will provide a business update and discuss financial results for the quarter ended June 30, 2023. Earlier this morning, we issued a press release with these results, which can be found under the investor section of our website. Joining on the call today by the following members of Longevron's management team. Mr. Weihall Ashad, Chief Executive Officer, Natalia Agafenova, Chief Medical Officer, and Lisa Locklear, Chief Financial Officer. Mr. Ashad will begin with a brief corporate overview, then Dr. Agafenova will review Longevron's recent progress in its clinical programs, and Ms. Locklear will review financial results for the 2023 second quarter. Following the company's prepared remarks, we will open the call to questions from covering analysts. As a reminder, during this call, we will be making forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussed in our filings with the SEC, including our quarterly report on Form 10Q and annual report on Form 10K, and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information. Now, I'd like to turn the call over to Mr. Wael Ashad, Chief Executive Officer of Longeverone. Wael?